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Phase I/II trial 
a b s t r a c t 
We analyzed potential biomarkers of response to ibrutinib plus nivolumab in biopsies from patients with diffuse 
large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and Richter’s transformation (RT) from the LYM1002 
phase I/IIa study, using programmed death ligand 1 (PD-L1) immunohistochemistry, whole exome sequencing 
(WES), and gene expression profiling (GEP). In DLBCL, PD-L1 elevation was more frequent in responders versus 
nonresponders (5/8 [62.5%] vs. 3/16 [18.8%]; p = 0.065; complete response 37.5% vs. 0%; p = 0.028). Overall 
response rates for patients with WES and GEP data, respectively, were: DLBCL (38.5% and 29.6%); FL (46.2% 
and 43.5%); RT (76.5% and 81.3%). In DLBCL, WES analyses demonstrated that mutations in RNF213 (40.0% vs. 
6.2%; p = 0.055), KLHL14 (30.0% vs. 0%; p = 0.046), and LRP1B (30.0% vs. 6.2%; p = 0.264) were more frequent 
in responders. No responders had mutations in EBF1, ADAMTS20, AKAP9, TP53, MYD88 , or TNFRSF14 , while the 
frequency of these mutations in nonresponders ranged from 12.5% to 18.8%. In FL and RT, genes with different 
mutation frequencies in responders versus nonresponders were: BCL2 (75.0% vs. 28.6%; p = 0.047) and ROS1 
(0% vs. 50.0%; p = 0.044), respectively. Per GEP, the most upregulated genes in responders were LEF1 and BTLA 
(overall), and CRTAM (germinal center B-cell–like DLBCL). Enriched pathways were related to immune activation 
in responders and resistance-associated proliferation/replication in nonresponders. This preliminary work may 
help to generate hypotheses regarding genetically defined subsets of DLBCL, FL, and RT patients most likely to 

















Among novel targeted therapies for the treatment of B-cell malig-
ancies, ibrutinib, a first-in-class, oral, covalent inhibitor of Bruton’s
yrosine kinase (BTK), improved clinical outcomes in randomized trials
n patients with treatment-naive or relapsed/refractory non-Hodgkin’s✩ Congress Presentation 
✩✩ Part of the results was presented at the American Association for Cancer Research
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exclusivamente. No se permiten otros usos sin autorización. Copyymphoma (NHL) [1–9] leading to approval of ibrutinib in the United
tates and Europe for the treatment of adult B-cell malignancies, and
lso for chronic graft versus host disease (cGVHD) [ 10 , 11 ]. 
Ibrutinib is an investigational therapy for diffuse large B-cell lym-
homa (DLBCL), follicular lymphoma (FL), and Richter’s transforma-
ion (RT), and responses have been observed in phase I/II studies in
atients with treatment-naive [12] and relapsed/refractory disease [13–
5] . However, the prognosis for patients with relapsed disease remains 2019 Meeting in Atlanta, GA, USA, March 29–April 3, 2019. 
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d  oor [16] , and the synergistic antitumor activity of ibrutinib combined
ith other novel agents is currently being investigated as an approach
o improve long-term outcomes. 
Nivolumab is a fully human immunoglobulin G4 monoclonal anti-
ody that blocks interaction between the programmed death 1 (PD-1)
eceptor and its ligands, PD-L1 and PD-L2, and augments antitumor ac-
ivity of T cells [17] . High expression of PD-L1 in solid tumors and lym-
homas is generally thought to be related to greater response to anti-
D-1 therapy, but the results from clinical trials are conflicting [ 17 , 18 ].
ased on data from a phase II study [19] , nivolumab was approved in the
nited States for the treatment of classic Hodgkin’s lymphoma [20] and
as been investigated as monotherapy in DLBCL and FL [ 21 , 22 ], and in
ombination with ibrutinib in RT [23] . 
The phase I/IIa LYM1002 study (NCT02329847) evaluated the ef-
cacy and safety of ibrutinib plus nivolumab in 141 patients with re-
apsed/refractory B-cell malignancies [24] . Safety was consistent with
hat reported for single-agent ibrutinib or nivolumab. The overall re-
ponse rate (ORR) was 22/36 (61%) for patients with chronic lympho-
ytic leukemia/small lymphocytic lymphoma CLL/SLL (including pa-
ients with del17p/del11q), 13/40 (33%) for FL, 16/45 (36%) for DL-
CL, and 13/20 (65%) for RT. Response to ibrutinib plus nivolumab in
T was high; historically, these patients have had poor outcomes with
hemotherapy [25] or single-agent ibrutinib [26] . 
Biomarker analyses can enhance the efficacy of molecularly tar-
eted therapies by improving rational combinations and identifying pa-
ients most likely to benefit from the therapies. Whole genome or ex-
me sequencing studies have identified the spectrum of mutations in
enes known to be functionally relevant in DLBCL [ 27 , 28 ], and re-
ealed mutations driving initiation and progression of FL ( CREBBP,
ZH2, KMT2D, EBF1, MYD88, TNFAIP3 ) [29] and RT ( MYC, BCL2,
DKN2A,TP53, TNFRSF14, TNFSF9 ) [30] . Some gene mutations, includ-
ng CD79B, TP53, CARD11, MYD88, EZH2, KMT2D, TNFRSF14, BTG1,
EF2B , and GNA13 , have been implicated in the pathogenesis of DLBCL
27] . Exploration of gene variants that may impact response to ibrutinib
herapy in NHL (such as BCR and MYD88 pathway mutations in DLBCL
nd CARD11 mutations in DLBCL and FL) [ 13 , 14 ] is limited and requires
urther examination. 
This analysis evaluated the associations between response to ibruti-
ib plus nivolumab and a variety of biomarkers including PD-L1 expres-
ion by immunohistochemistry (IHC), DNA exome sequencing, and gene
xpression profiling (GEP), including pathway analyses. Analyses were
erformed using biopsy samples collected at baseline or before start of
reatment from patients with DLBCL (including subtypes), FL, and RT
nrolled in the LYM1002 study. 
ethods 
atients and study design 
Detailed methodology for the LYM1002 study (NCT02329847) was
ublished previously; the study was approved by an independent ethics
ommittee, and all patients provided written informed consent [24] .
riefly, this nonrandomized, open-label phase I/IIa study enrolled adult
atients with NHL who received intravenous nivolumab (3 mg/kg)
nce per 14-day cycle combined with oral ibrutinib 420 mg or 560 mg
nce daily. Key eligibility criteria were histologically confirmed re-
apsed/refractory CLL/SLL (with del17p or del11q), DLBCL, FL, or RT
transformation from CLL/SLL only), ≥ 1 prior systemic therapy ( ≥ 2 for
L) but no more than four prior lines of treatment, Eastern Coopera-
ive Oncology Group (ECOG) performance status ≤ 2, measurable dis-
ase, and no prior ibrutinib or anti-PD-1 therapy. Patients were excluded
or (a) having major surgery within 4 weeks of the first dose of ibruti-
ib, (b) getting diagnosed or treated for malignancies other than the
ndication under study, or (c) requiring treatment with either strong
YP3A inhibitors or warfarin (including equivalent vitamin K antago-Descargado para Anonymous User (n/a) en Vall d'Hebron Hospital de C
exclusivamente. No se permiten otros usos sin autorización. Copyists). Biomarker analyses presented herein were conducted in patients
ith DLBCL, FL, and RT for whom tumor tissue samples were available.
ssessments 
LBCL subtyping 
DLBCL subtyping, based on the Wright et al. classification al-
orithm [31] , was conducted in the R software environment using
AS5-normalized (affy v1.48.0, Bioconductor) baseline formalin-fixed
araffin-embedded (FFPE) biopsy GEP data (GeneChip Human Genome
133 Plus 2.0 Array; Affymetrix, Santa Clara, CA, USA). 
reatment response and survival outcomes 
Preliminary activity and clinical response to treatment were evalu-
ted by radiological assessments every five cycles for the first 15 months
nd every 12 cycles thereafter until disease progression, at the end of
reatment, and every 6 months during the follow-up period for patients
ho had not progressed while on therapy and did not start subsequent
herapy. Response was assessed per Lugano Classification by Cheson for
LBCL, FL, and RT [32] . For calculation of ORR, responders were de-
ned as patients who achieved complete response (CR) or partial re-
ponse (PR) by investigator assessment. Progression-free survival (PFS)
nd overall survival (OS) were estimated using the Kaplan-Meier method
nd log-rank tests were performed to assess significance. 
iomarker analyses and correlation with clinical outcome 
D-L1 expression 
PD-L1 expression as a predictive biomarker for clinical outcomes was
valuated by IHC from baseline tissue biopsies. PD-L1 levels were as-
essed by IHC as the percentage of tumor cells demonstrating plasma
embrane PD-L1 staining of any intensity in a minimum of 100 evalu-
ble tumor cells using the Dako PD-L1 IHC 28–8 pharmDx assay (Agilent
echnologies, Glostrup, Denmark). PD-L1 elevation was defined as ex-
ression in ≥ 5% of tumor cells. Kaplan-Meier survival probability with
esponse or survival endpoints was calculated for patients with elevated
r nonelevated PD-L1 subgroups with DLBCL, FL, and RT. The associ-
tion of PD-L1 with clinical response was assessed using Fisher’s exact
est. 
NA sequence analyses 
Exome data were generated from FFPE samples, each from
 different patient at baseline. Raw Illumina FASTQ files were
rocessed as follows on the DNAnexus platform (DNAnexus Inc;
ttps://www.dnanexus.com/ ) using a custom exome analysis workflow:
uality was assessed using FastQC 1.0.0, sequences were aligned to the
s37d5 genome build using the BWA-MEM algorithm in BWA Software
ackage 0.5.9, alignments were recalibrated with the GATK 3.5 Exome
ipeline, variants were annotated with MuTect 1.1.7, and annotations
ere made with both SnpEff 4.2 (using the GRCh37.75 database and
bNSFP 3.4c) and GEMINI 0.20.0 (modified by using “non-TCGA ” gno-
AD and ExAC references). 
Mutation analysis was performed on a set of cancer-related genes of
nterest ( n = 1742), including those from DLBCL-associated genes (ie, ac-
ivated B-cell–like [ABC]/germinal center B-cell–like [GCB] discriminat-
ng genes, genes used to discriminate between four recently defined sub-
ypes, genes predicted as hypermutated in DLBCL) [33] , and genes pre-
iously identified from ibrutinib studies, focusing on nonsynonymous
ingle-nucleotide variants that are likely to be somatic based on a set of
efined criteria (Supplementary Figure S1). A number of variant filters
ere used to reduce the likelihood of incorporating sequencing artifacts
nd germline variants into the analyses. 
The significance of variant frequency differences between treat-
ent responders (CR + PR) versus nonresponders (no response or sta-
le disease [SD] + progressive disease [PD]), and between patients with
urable responses (PFS > 24 months) versus those with PFS ≤ 24 months ,linicalKey.es por Elsevier en junio 14, 2021. Para uso personal 
right ©2021. Elsevier Inc. Todos los derechos reservados.
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Table 1 
Responses in Patients with DLBCL, FL, and RT who had GEP and WES Data. 
GEP Data Set Total DLBCL a FL RT 
N = 66 All n = 27 ABC n = 5 GCB n = 18 n = 23 n = 16 
ORR (CR + PR), n (%) 31 (47.0) 8 (29.6) 2 (40.0) 6 (33.3) 10 (43.5) 13 (81.3) 
CR, n (%) 9 (13.6) 4 (14.8) 2 (40.0) 2 (11.1) 3 (13.1) 2 (12.5) 
PR, n (%) 22 (33.3) 4 (14.8) 0 4 (22.2) 7 (30.4) 11 (68.8) 
Nonresponders, n (%) 35 (53.0) 19 (70.4) 3 (60.0) 12 (66.7) 13 (56.5) 3 (18.8) 
No response or SD, n (%) 10 (15.2) 4 (14.8) 0 2 (11.1) 6 (26.1) 0 
PD, n (%) 25 (37.9) 15 (55.6) 3 (60.0) 10 (55.6) 7 (30.4) 3 (18.8) 
WES Data Set Total DLBCL FL RT 
N = 69 All n = 26 ABC n = 4 GCB n = 16 n = 26 n = 17 
ORR (CR + PR), n (%) 35 (50.7) 10 (38.5) 2 (50.0) 6 (37.5) 12 (46.2) 13 (76.5) 
CR, n (%) 10 (14.5) 5 (19.2) 2 (50.0) 2 (12.5) 3 (11.5) 2 (11.8) 
PR, n (%) 25 (36.2) 5 (19.2) 0 4 (25.0) 9 (34.6) 11 (64.7) 
Nonresponders, n (%) 34 (49.3) 16 (61.5) 2 (50.0) 10 (62.5) 14 (53.8) 4 (23.5) 
No response or SD, n (%) 12 (17.4) 4 (15.4) 0 2 (12.5) 8 (30.8) 0 
PD, n (%) 22 (31.9) 12 (46.2) 2 (50.0) 8 (50.0) 6 (23.1) 4 (23.5) 
a All DLBCL patient set also includes patients with unclassified and/or transformed DLBCL not outlined 
in the Table.ABC, activated B-cell–like; CR, complete response; DLBCL, diffuse large B-cell lymphoma; 
FL, follicular lymphoma; GCB, germinal center B-cell–like; GEP, gene expression profiling; NHL, non- 
Hodgkin’s lymphoma; ORR, overall response rate; PD, progressive disease; PR, partial response; PRL, 




































































I  ere examined gene-by-gene using Fisher’s exact test (no adjustments
or multiple hypothesis testing). Patients with no response data were
ot included in the analyses. Differences in tumor mutational burden
TMB), calculated by dividing the number of inferred somatic mutations
n each sample by 30 Mb (the approximate size of the whole exome),
ere assessed using the Wilcoxon rank sum test. 
For patients with DLBCL, mutations were examined in terms of func-
ional groupings by tying mutations in particular genes to potential dys-
egulation of certain pathways and counting the number of patients with
uch mutations. Supplementary Table S1 shows which genes were cho-
en and the functional groups to which they were assigned. 
ene expression analyses 
Gene expression microarray data were generated from baseline FFPE
iopsy samples using the GeneChip Human Genome U133 Plus 2.0 Ar-
ay. CEL files were processed and analyzed for DGE and DLBCL sub-
yping using the R software environment. Raw data were prepared for
GE analyses by Robust Multichip Average normalization (affy v1.48.0,
ioconductor) and annotation with the University of Michigan BrainAr-
ay CDF (hgu133plus2hsentrezgcdf, v20.0.0); DGE analyses were per-
ormed with empirical Bayes moderation (limma v3.40.6, Bioconductor)
nd resulting p values were adjusted using the Benjamini-Hochberg false
iscovery rate-controlling method for multiple hypothesis testing. Gene
et enrichment analyses were performed to assess enrichment of canon-
cal pathways from the C2 collection of gene sets from mSigDB. Genes
ere preranked according to log FC values (from aforementioned DGE
esults) and analyzed using the Java-based application gsea2–2.2.0.jar
ith default parameters. 
esults 
atients and treatment 
Baseline demographics and primary efficacy and safety results for
YM1002 have been reported previously [24] . Briefly, between March
2, 2015 and April 11, 2017, 141 patients were enrolled and treated
ith daily oral ibrutinib (420 mg or 560 mg) plus intravenous nivolumab
3 mg/kg every 2 weeks): relapsed/refractory CLL/SLL ( n = 36; del17pDescargado para Anonymous User (n/a) en Vall d'Hebron Hospital de C
exclusivamente. No se permiten otros usos sin autorización. Copy = 19, del11q n = 17), DLBCL ( n = 45), FL ( n = 40), and RT ( n = 20). At
he time of clinical cutoff on October 10, 2017, 35/141 (25%) patients
emained on treatment (13 with CLL/SLL, 9 with DLBCL, 7 with FL,
nd 6 with RT). The most common reasons for treatment discontinua-
ion in all patients were progressive disease or relapse (39%) and ad-
erse events (28%). Median age was 65 years (interquartile range [IQR]
4.0–71.0), 87 (62%) patients were male, 130 (93%) had an ECOG per-
ormance status of 0 to 1, and 68 (48%) had bulky disease ( ≥ 5 cm). The
edian number of prior lines of treatment was three. Median follow-up
or patients included in this analysis was 18.4 months (IQR 14.8–19.4)
or DLBCL, 19.6 months (IQR 14.1–20.7) for FL, and 8.7 months (IQR
.5–12.1) for RT. 
LBCL subtyping 
Twenty-eight patients with DLBCL were evaluable for subtyping us-
ng the GEP microarray method; most (19/28) had the GCB subtype,
ve had the ABC subtype, and four were unclassified. 
reatment responses 
Of 70 patients (DLBCL + FL + RT) who had GEP data, 66 were evalu-
ble for response. ORRs were 47.0% (31/66) for all patients, 29.6%
8/27) for DLBCL, 33.3% (6/18) for GCB DLBCL, and 43.5% (10/23)
or FL. ORR was highest for patients with RT (81.3%; 13/16) ( Table 1 ).
Rs were reported in four patients with DLBCL (two with GCB and two
ith ABC), three with FL, and two with RT. 
Of 72 patients who had WES data, 69 were evaluable for response.
RRs were 50.7% (35/69) for all patients, 38.5% (10/26) for DLBCL,
7.5% (6/16) for GCB DLBCL, 46.2% (12/26) for FL, and 76.5% (13/17)
or RT ( Table 1 ). CRs were reported in five patients with DLBCL (two
ith GCB, two with ABC, and 1 with unclassified DLBCL), three with
L, and two with RT ( Table 1 ). 
linical outcome analyses by biomarker 
D-L1 expression 
Twenty-six patients with DLBCL, 25 with FL, and 15 with RT had
HC-based PD-L1 data available for analysis. Because only 1 of 25 pa-linicalKey.es por Elsevier en junio 14, 2021. Para uso personal 
right ©2021. Elsevier Inc. Todos los derechos reservados.
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Fig. 1. PFS and OS by IHC-based PD-L1 expression in patients with DLBCL ( A and B ) and GCB DLBCL ( C and D ). The numbers below the X-axis depict patients at 
risk of progression who had elevated PD-L1 and those who did not have elevated PD-L1. DLBCL, diffuse large B-cell lymphoma; GCB, germinal center B-cell–like; 









































N  ients with FL had PD-L1 elevation ( ≥ 5% tumor cells by IHC), this anal-
sis focused on patients with DLBCL and RT. Among the 26 patients
ith DLBCL who had IHC data, 18 patients had PD-L1 expression < 5%
range 0–2%) and 8 patients had PD-L1 expression ≥ 5% (range 5–95%),
ith the mean (standard deviation [SD]) of 9.6 (21.6)% (Supplementary
igure S2). Of the 8 patients with elevated PD-L1, three had a CR and
wo had PRs. Of the 26 DLBCL patients with IHC data, 24 also had GEP-
ased subtyping calls, with six (25.0%) having elevated PD-L1; among
hese patients, four had GCB DLBCL (one CR, two PRs, and one SD), one
ad ABC DLBCL (PD), and one was unclassified (PD) (Supplementary
able S2). Based on the IHC analysis, elevated PD-L1 in DLBCL ( ≥ 5%
umor cells positive for PD-L1) was observed more frequently in respon-
ers versus nonresponders (62.5% [5/8] vs. 18.8% [3/16]; p = 0.065)
nd was significantly associated with CR (37.5% [3/8] vs. 0% [0/16];
 = 0.028). There was a trend toward improved PFS and OS in patients
ith DLBCL or GCB DLBCL who had elevated PD-L1 ( Fig. 1 ). In RT, 3/15
20.0%) patients with available IHC data had elevated PD-L1; all three
ad PRs with durable PFS and OS. At study closure, two of the three pa-
ients with elevated PD-L1 had not progressed, and all three were alive,
ut no significant correlation could be established because of the small
umber of patients. Descargado para Anonymous User (n/a) en Vall d'Hebron Hospital de C
exclusivamente. No se permiten otros usos sin autorización. Copyxome analyses 
esponders versus nonresponders 
Exome and response data were available for 26 patients with DLBCL
ORR 38.5%; 10 responders [5 CR, 5 PR], 16 nonresponders), 16 with
CB DLBCL (ORR 37.5%; 6 responders [2 CR, 4 PR], 10 nonresponders),
6 with FL (ORR 46.2%; 12 responders [3 CR, 9 PR], 14 nonresponders),
nd 17 with RT (ORR 76.5%; 13 responders [2 CR, 11 PR], 4 nonrespon-
ers). 
DLBCL responders versus nonresponders were more likely to have
utations in RNF213 (4/10 [40.0%] vs. 1/16 [6.2%]), KLHL14 (3/10
30.0%] vs. 0/16), LRP1B (3/10 [30.0%] vs. 1/16 [6.2%]), and OS-
PL10 (3/10 [30.0%] vs. 1/16 [6.2%]) ( Table 2 , Fig. 2 ). The difference
n expression between responders and nonresponders was highest for
LHL14 ( p = 0.046) Fig. 2 is a heatmap of the frequently occurring mu-
ations from the gene set of interest occurring in patients with DLBCL
y responder and nonresponder status, sorted by p values within the re-
ponder gene block (top four genes) and the nonresponder gene block
all other genes). DLBCL nonresponders commonly had variants in EBF1,
DAMTS20 , and AKAP9. Mutations in the BCR pathway ( TNFRSF14,
FKB1B ), epigenetic modifiers ( CREBBP, KMT2D ), and other signalinglinicalKey.es por Elsevier en junio 14, 2021. Para uso personal 
right ©2021. Elsevier Inc. Todos los derechos reservados.
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Table 2 
Frequent Differentially Mutated Genes between Responders and Nonresponders in Diffuse Large 
B-Cell Lymphoma (Occurring in at Least Three Patients in Either Group). 
Gene Responders( n = 10) Nonresponders( n = 16) Odds Ratio (95% CI) p Value 
Mutations more frequent in responders 
KLHL14 3 (30.0%) 0 (0.0%) Inf (0.730–Inf) 0.046 
RNF213 4 (40.0%) 1 (6.2%) 9.053 (0.711–522.371) 0.055 
LRP1B 3 (30.0%) 1 (6.2%) 5.950 (0.397–358.476) 0.264 
OSBPL10 3 (30.0%) 1 (6.2%) 5.950 (0.397–358.476) 0.264 
Mutations more frequent in nonresponders 
EBF1 0 (0.0%) 4 (25.0%) 0.000 (0.000–2.304) 0.136 
ADAMTS20 0 (0.0%) 3 (18.8%) 0.000 (0.000–3.825) 0.262 
AKAP9 0 (0.0%) 3 (18.8%) 0.000 (0.000–3.825) 0.262 
CHD8 0 (0.0%) 3 (18.8%) 0.000 (0.000–3.825) 0.262 
CSDE1 0 (0.0%) 3 (18.8%) 0.000 (0.000–3.825) 0.262 
EML4 0 (0.0%) 3 (18.8%) 0.000 (0.000–3.825) 0.262 
GPR124 0 (0.0%) 3 (18.8%) 0.000 (0.000–3.825) 0.262 
KIAA1109 0 (0.0%) 3 (18.8%) 0.000 (0.000–3.825) 0.262 
KLF2 0 (0.0%) 3 (18.8%) 0.000 (0.000–3.825) 0.262 
MDC1 0 (0.0%) 3 (18.8%) 0.000 (0.000–3.825) 0.262 
MEF2C 0 (0.0%) 3 (18.8%) 0.000 (0.000–3.825) 0.262 
SOCS1 0 (0.0%) 3 (18.8%) 0.000 (0.000–3.825) 0.262 
SPTA1 0 (0.0%) 3 (18.8%) 0.000 (0.000–3.825) 0.262 
TNFRSF14 0 (0.0%) 3 (18.8%) 0.000 (0.000–3.825) 0.262 
TP53 0 (0.0%) 3 (18.8%) 0.000 (0.000–3.825) 0.262 
CREBBP 1 (10.0%) 5 (31.2%) 0.257 (0.005–2.940) 0.352 
KMT2D 2 (20.0%) 6 (37.5%) 0.430 (0.034–3.353) 0.42 
BCL7A 1 (10.0%) 4 (25.0%) 0.346 (0.006–4.350) 0.617 
HIST1H1C 1 (10.0%) 4 (25.0%) 0.346 (0.006–4.350) 0.617 
HIST1H1E 1 (10.0%) 4 (25.0%) 0.346 (0.006–4.350) 0.617 
SGK1 1 (10.0%) 4 (25.0%) 0.346 (0.006–4.350) 0.617 
CSMD3 3 (30.0%) 7 (43.8%) 0.564 (0.068–3.754) 0.683 
CI, confidence interval. 
Fig. 2. Diffuse large B-cell lymphoma gene-level mutation 
heatmap showing variants from panel of interest occurring 
in at least three patients, by responder status. Each vertical 





















athways were also observed ( Table 2 , Fig. 3 ). Mutations in HIST1H1C,
CL7A , and SGK1 were reported in both responders and nonresponders
ut were generally more frequent in nonresponders ( Table 2 ). 
Gene mutations implicated in the pathogenesis of DLBCL [27] were
enerally more frequent in nonresponders (Supplementary Table S2).
one of the DLBCL responders had mutations in TP53, MYD88, GNA13,
nd TNFRSF14 , while frequency of these mutations in nonresponders
anged from 12.5% to 18.8%. Of note, there were two mutations in
YD88 (both in nonresponders) and one in CARD11 (in a responder).
n DLBCL, a trend toward more BCR pathway–associated mutations wasDescargado para Anonymous User (n/a) en Vall d'Hebron Hospital de C
exclusivamente. No se permiten otros usos sin autorización. Copybserved in nonresponders, with 10% (1/10) of responders and 50%
8/16) of nonresponders having mutations associated with BCR signal-
ng ( p = 0.087). 
In the GCB DLBCL subset, there were no gene variants that reached
ignificance between responders and nonresponders (Supplementary Ta-
le S3). The most differentially expressed gene mutations were more
requent in nonresponders versus responders: CSMD3 (5/10 [50%] vs.
/6 [0%], p = 0.093); BCL2 (6/10 [60.0%] vs. 1/6 [16.7%], p = 0.145);
MT2D (6/10 [60.0%] vs. 1/6 [16.7%], p = 0.145); CREBBP, EBF1 , and
GK1 (all 4/10 [40.0%] vs. 0/6 [0%], p = 0.234). linicalKey.es por Elsevier en junio 14, 2021. Para uso personal 
right ©2021. Elsevier Inc. Todos los derechos reservados.
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Fig. 3. Functional groups of mutated genes in patients with diffuse large B-cell 
lymphoma. The pie chart shows the number of patients ( N = 52) with somatic 







































































































o  Mutation frequencies differing for responders versus nonresponders
n FL and RT, respectively, were in BCL2 (9/12 [75.0%] vs. 4/14
28.6%]; p = 0.047) and ROS1 (0/13 vs. 2/4 [50.0%]; p = 0.044). No ma-
or differences were observed in overall TMB between responders and
onresponders with DLBCL ( p = 0.215), FL ( P = .899), or RT ( p = 1.000);
owever, in GCB DLBCL, TMB was substantially lower for responders
 p = 0.003) (Supplementary Figure S3A-D). 
FS > 24 versus ≤ 24 months in DLBCL 
In DLBCL, RNF213 (3/7 [42.9%]) , NBPF1 (3/7 [42.9%]) , KLHL14
2/7 [28.6%]), and LRP1B (2/7 [28.6%]) variants were more often seen
n patients with PFS > 24 months. In patients with PFS ≤ 24 months,
he most common variants included KMT2D (8/20 [40.0%]), CREBBP
6/20 [30.0%]), HIST1H1E (5/20 [25.0%]), EP400 (4/20 [20.0%]), and
DE4DIP (6/20 [30.0%]), all of which are involved in chromatin struc-
ure; EBF1 (4/20 [20.0%]), CD79B, TP53, ADAMTS20, AKAP9 , and TN-
RSF14 (all 3/20 [15.0%]) variants were also seen ( Table 3 ). The TMB
as substantially lower in DLBCL patients with PFS > 24 versus ≤ 24
onths ( p = 0.0288) (Supplementary Figure S3E). 
ene expression profiling analysis 
ifferential gene expression 
Gene expression and response data were available for 66 patients.
he 20 most common genes that were differentially expressed in re-
ponders versus nonresponders (all increased in responders) are listed
n Table 4 . LEF1 and BTLA were the most upregulated genes in respon-
ers for all patients included in this analysis (DLBCL + FL + RT). The top
0 genes upregulated and downregulated in responders with DLBCL, FL,
nd RT are summarized in Supplementary Tables S4, S5, and S6. In GCB
LBCL, CRTAM was a top gene upregulated (2.25-fold) in the responder
roup. 
athway-level gene set enrichment analysis 
Among all patients included in this analysis, pathway enrichment re-
ults were available for 41 ibrutinib plus nivolumab responders and 37
onresponders. Among various histologies, responder and nonrespon-
er results, respectively, were available for 8 and 19 patients with DL-
CL, 10 and 13 patients with FL, and 13 and 3 patients with RT. Over-
ll, pathways upregulated in responders to ibrutinib plus nivolumab re-
ated mostly to RNA translation/metabolism, IL-12 signaling, TCR sig-
aling, IFN-gamma signaling, cytokine/chemokine activity, and general
mmune activation ( Table 5 ). Nonresponders had enriched activity inDescargado para Anonymous User (n/a) en Vall d'Hebron Hospital de C
exclusivamente. No se permiten otros usos sin autorización. Copyathways related to the extracellular matrix (ECM) processing (eg, gly-
oproteins, collagen, ECM organization, and general matrisome activity;
able 5 ). The most enriched pathways in responders and nonresponders
ith DLBCL, FL, and RT are summarized in Supplementary Tables S7,
8, and S9. 
The pathways with greater activation in the DLBCL nonresponders
ere predominantly related to cell cycle, DNA replication, and RNA
plicing/processing/metabolism (Supplementary Table S7). The respon-
ers with FL had enrichment of activity in pathways related to RNA
plicing/processing/metabolism (Supplementary Table S8). 
iscussion 
Reliable disease subtype identification in patients receiving novel
herapies is an important step toward personalizing treatment for pa-
ients with relapsed/refractory B-cell malignancies, who have limited
ptions for achieving durable responses. Further, biomarker analyses
an help identify patients most likely to benefit from molecularly tar-
eted therapies. This analysis evaluated several potential biomarkers of
esponse to combined treatment with ibrutinib and nivolumab in pa-
ients with DLBCL (subtyped using GEP and HTG methods), FL, and RT,
sing data from the primary LYM1002 phase I/IIa study. 
Among patients who had both GEP and response data, good re-
ponses to treatment were noted in all cohorts, with the highest re-
ponse rate in RT (81.3%). Patients with DLBCL had an ORR of 29.6%.
esponses were more frequent in patients with the GCB subtype (6/18
33.3%]), which is in contrast to the ORR of 5% reported previously
or single-agent ibrutinib [13] . These results, with the caveat of limited
ample size and no central review of GCB status, suggest that ibrutinib in
ombination with nivolumab may have increased efficacy in this patient
opulation. 
PD-L1 expression was investigated in various solid tumors treated
ith nivolumab, using the definition of PD-L1 positivity as ≥ 5% cell
embrane staining of any intensity [34] . DLBCL tumors often express
D-L1 [35–38] , and analyzing expression of PD-L1 in DLBCL using
iopsy samples and a 5% threshold for PD-L1 positivity reported vary-
ng percentages of PD-L1–positive DLBCL, ranging from 11% to 49%
 35 , 37 , 38 ]. In this study, approximately 30% of patients with DLBCL
including the GCB and ABC subtypes) had elevated PD-L1 expression
y IHC. Studies in large groups of patients suggest that non-GCB DL-
CL is more commonly associated with PD-L1 expression, although it
s observed within both GCB and ABC subtypes [ 35 , 36 ]. Patients with
LBCL and PD-L1 elevation showed a trend toward improved response
ates and prolonged survival with ibrutinib and nivolumab, with statis-
ical significance reached for the association between PD-L1 expression
nd CR ( p = 0.028). These results are promising, particularly as PD-L1
ositivity in tumor cells has been associated with poor outcomes (partic-
larly OS) to rituximab, cyclophosphamide, doxorubicin vincristine, and
rednisone (R-CHOP) or R-CHOP–based regimens in DLBCL [ 35 , 36 ]. All
hree patients with RT and elevated PD-L1 achieved PRs and none of
hem experienced PD during the course of the study. However, mean-
ngful correlations between PD-L1 status and RT outcome were not pos-
ible due to the small sample size. Only one patient with FL had PD-L1
levation; previous research indicates that PD-L1 expression is rare in
his malignancy [ 39 , 40 ]. In a recent phase II study, nivolumab showed
ery limited activity in relapsed/refractory FL (ORR 4%), and no corre-
ation between PD-1 or PD-L1 expression and response was noted [22] .
n view of this result, the high response in FL observed in our study
43.5%) might have been driven mostly by ibrutinib, consistent with
ingle-agent ibrutinib achieving ORR of 37.5% in a phase II study in
elapsed/refractory FL [14] . 
Further investigation of the combination of BTK and PD-L1 inhibitor
herapy is ongoing in B-cell malignancies and could help identify his-
ologies for which this treatment strategy is likely to be most benefi-
ial. Ongoing phase I/II studies are evaluating the safety and efficacy
f ibrutinib combined with nivolumab (NCT02420912, NCT02940301)linicalKey.es por Elsevier en junio 14, 2021. Para uso personal 
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Table 3 
Frequent Differentially Mutated Genes Between Patients with PFS > 24 versus ≤ 24 Months in Diffuse 
Large B-Cell Lymphoma (Occurring in at Least Three Patients Overall). 
Gene PFS > 24 Months( n = 7) PFS ≤ 24 Months( n = 20) Odds Ratio (95% CI) p Value 
Mutations more frequent in patients with PFS > 24 months 
RNF213 3 (42.9%) 2 (10.0%) 6.147 (0.527–97.903) 0.091 
KLHL14 2 (28.6%) 1 (5.0%) 6.889 (0.303–469.371) 0.156 
LRP1B 2 (28.6%) 2 (10.0%) 3.398 (0.200–58.569) 0.269 
TRIO 2 (28.6%) 2 (10.0%) 3.398 (0.200–58.569) 0.269 
NBPF1 3 (42.9%) 4 (20.0%) 2.863 (0.298–26.744) 0.328 
MEF2B 2 (28.6%) 3 (15.0%) 2.190 (0.145–25.665) 0.580 
SGK1 2 (28.6%) 3 (15.0%) 2.190 (0.145–25.665) 0.580 
IGLL5 2 (28.6%) 4 (20.0%) 1.571 (0.111–15.591) 0.633 
BCL2 3 (42.9%) 6 (30.0%) 1.712 (0.191–14.078) 0.653 
Mutations more frequent in patients with PFS < 24 months 
CREBBP 0 (0.0%) 6 (30.0%) 0.000 (0.000–2.315) 0.155 
PDE4DIP 0 (0.0%) 6 (30.0%) 0.000 (0.000–2.315) 0.155 
HIST1H1E 0 (0.0%) 5 (25.0%) 0.000 (0.000–3.101) 0.283 
KMT2D 1 (14.3%) 8 (40.0%) 0.261 (0.005–2.854) 0.363 
ADAMTS20 0 (0.0%) 3 (15.0%) 0.000 (0.000–7.204) 0.545 
AKAP9 0 (0.0%) 3 (15.0%) 0.000 (0.000–7.204) 0.545 
ANK3 0 (0.0%) 3 (15.0%) 0.000 (0.000–7.204) 0.545 
CD79B 0 (0.0%) 3 (15.0%) 0.000 (0.000–7.204) 0.545 
CHD8 0 (0.0%) 3 (15.0%) 0.000 (0.000–7.204) 0.545 
CSDE1 0 (0.0%) 3 (15.0%) 0.000 (0.000–7.204) 0.545 
EML4 0 (0.0%) 3 (15.0%) 0.000 (0.000–7.204) 0.545 
EP400 0 (0.0%) 4 (20.0%) 0.000 (0.000–4.440) 0.545 
GPR124 0 (0.0%) 3 (15.0%) 0.000 (0.000–7.204) 0.545 
HIST1H2AC 0 (0.0%) 3 (15.0%) 0.000 (0.000–7.204) 0.545 
KIAA1109 0 (0.0%) 3 (15.0%) 0.000 (0.000–7.204) 0.545 
KLF2 0 (0.0%) 3 (15.0%) 0.000 (0.000–7.204) 0.545 
MAP3K1 0 (0.0%) 3 (15.0%) 0.000 (0.000–7.204) 0.545 
MDC1 0 (0.0%) 3 (15.0%) 0.000 (0.000–7.204) 0.545 
MEF2C 0 (0.0%) 3 (15.0%) 0.000 (0.000–7.204) 0.545 
SF3A1 0 (0.0%) 3 (15.0%) 0.000 (0.000–7.204) 0.545 
SLC4A5 0 (0.0%) 3 (15.0%) 0.000 (0.000–7.204) 0.545 
SPEN 0 (0.0%) 3 (15.0%) 0.000 (0.000–7.204) 0.545 
SPTA1 0 (0.0%) 3 (15.0%) 0.000 (0.000–7.204) 0.545 
SPTAN1 0 (0.0%) 3 (15.0%) 0.000 (0.000–7.204) 0.545 
TET2 0 (0.0%) 3 (15.0%) 0.000 (0.000–7.204) 0.545 
TNFRSF14 0 (0.0%) 3 (15.0%) 0.000 (0.000–7.204) 0.545 
TP53 0 (0.0%) 3 (15.0%) 0.000 (0.000–7.204) 0.545 
BTG1 0 (0.0%) 4 (20.0%) 0.000 (0.000–4.440) 0.545 
DCC 0 (0.0%) 4 (20.0%) 0.000 (0.000–4.440) 0.545 
EBF1 0 (0.0%) 4 (20.0%) 0.000 (0.000–4.440) 0.545 
EP400 0 (0.0%) 4 (20.0%) 0.000 (0.000–4.440) 0.545 
MUC17 0 (0.0%) 4 (20.0%) 0.000 (0.000–4.440) 0.545 
NRG1 0 (0.0%) 4 (20.0%) 0.000 (0.000–4.440) 0.545 
CSMD3 2 (28.6%) 8 (40.0%) 0.611 (0.047–4.995) 0.678 








































≤  r pembrolizumab (NCT03153202, NCT03514017, NCT03204188,
CT02332980, NCT03204188) in NHL or classic Hodgkin’s lymphoma.
Exome analyses were aimed at identifying gene mutations enriched
n patients who responded versus those who did not respond to treat-
ent with ibrutinib plus nivolumab. In DLBCL, the top three gene mu-
ations more frequently mutated in responders versus nonresponders in-
luded KLHL14 ( p = 0.046), RNF213 (p = 0.055), and LRP1B ( p = 0.264).
LHL14 belongs to the Kelch-like family of proteins that can serve as
ubunits of Cullin-RING ubiquitin ligase complex [41] highly expressed
n B cells, promoting B1a but suppressing B1b cell development in
ice, and thus revealing a role in controlling B cell differentiation [42] .
LHL14 is frequently mutated in ABC DLBCL cells [43] , and recent in
itro data have highlighted involvement of KLHL14 in BCR-dependent
F- 𝜅B activation [44] . Mutations in RNF213, the Moyamoya disease
ene product and an E3 ligase, have been reported in liver cancers
45] and RNF213-ALK fusion has been described in anaplastic large cell
ymphoma [46] . In HER2 + breast cancer cells, RNF213 was uncovered
o be a substrate for the protein-tyrosine phosphatase PTP1B, and both
roteins were required for survival of HER2 + breast cancer in the hy-
oxic tumor microenvironment [47] Mutations in LRP1B are frequent inDescargado para Anonymous User (n/a) en Vall d'Hebron Hospital de C
exclusivamente. No se permiten otros usos sin autorización. Copyelanoma and an association with response to PD-1 blockade has been
eported [48] . 
DLBCL nonresponders commonly had mutations in EBF1,
DAMTS20 , and AKAP9 genes generally involved in tumor initia-
ion/proliferation [49-51] . It has been suggested that mutations of
ARD11 (another gene implicated in NF- 𝜅B pathway activation down-
tream of BTK) predict lack of response to ibrutinib in DLBCL and FL
 13 , 14 ]. In our analyses of patients with DLBCL, nonresponders were
ore likely to have mutations in genes involved in alternate BCR path-
ays converging on NF- 𝜅B, such as TNFRSF14, MYD88 , and NFKB1B,
hich are among the genes implicated in the pathogenesis of DLBCL
nd recurrent in refractory disease [ 27 , 28 ]. Notably, none of the DLBCL
esponders had mutations in TP53, MYD88, and TNFRSF14 . Other gene
ariants occurred frequently but were not linked to response, such as
SMD3, BCL2, and NBPF1 . 
As mentioned, ibrutinib plus nivolumab had an unexpectedly high
ntitumor activity in GCB DLBCL, emphasizing the clinical benefit of
dding nivolumab to ibrutinib. However, overall TMB was lower in re-
ponders with GCB DLBCL and in DLBCL patients with PFS > 24 versus
 24 months, contrary to previous reports in non–small-cell lung car-linicalKey.es por Elsevier en junio 14, 2021. Para uso personal 
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Table 4 
The Top 20 Genes Differentially Expressed Between Responders and Nonresponders to Ibrutinib plus Nivolumab Among All Patients with Non-Hodgkin’s Lymphoma a . 
Gene Description Log FC Adjusted p Value 
Genes upregulated in the responder group 
LEF1 Lymphoid enhancer-binding 
factor 1 
1.058 0.001 
BTLA B and T lymphocyte associated 1.095 0.001 
PATL2 Protein associated with 
topoisomerase II homolog 2 
(yeast) 
1.111 0.003 
SIDT1 SID1 transmembrane family, 
member 1 
0.872 0.015 
PYHIN1 Pyrin and HIN domain family, 
member 1 
1.261 0.016 
L3MBTL3 l(3)mbt-like 3 (Drosophila) 0.982 0.028 
FAM114A2 Family with sequence similarity 
114, member A2 
0.545 0.028 
TBC1D15 TBC1 domain family, member 15 0.400 0.028 
LEPROTL1 Leptin receptor overlapping 
transcript-like 1 
0.817 0.028 
SACS Sacsin molecular chaperone 0.905 0.028 
LMBRD1 LMBR1 domain containing 1 0.808 0.028 
GCLC Glutamate-cysteine ligase, 
catalytic subunit 
1.150 0.028 
APOL3 Apolipoprotein L, 3 0.946 0.028 
SRBD1 S1 RNA binding domain 1 0.658 0.028 
TIGIT T cell immunoreceptor with Ig 
and ITIM domains 
0.562 0.032 
CCL4 Chemokine (C –C motif) ligand 4 0.697 0.032 
MDM1 Mdm1 nuclear protein 0.725 0.032 
SUB1 SUB1 homolog, transcriptional 
regulator 
0.850 0.032 
FCMR Fc fragment of IgM receptor 1.378 0.032 
GMFG Glia maturation factor, gamma 0.547 0.035 
Genes downregulated in the responder group 
C5orf66 Chromosome 5 open reading 
frame 66 
–0.503 0.053 
PAPPA Pregnancy-associated plasma 
protein A, pappalysin 1 
–0.442 0.056 
CCDC120 Coiled-coil domain containing 
120 
–0.331 0.061 
SOX9 SRY (sex determining region 
Y)-box 9 
–1.061 0.066 
STS Steroid sulfatase (microsomal), 
isozyme S 
–0.421 0.067 
LYPD6B LY6/PLAUR domain containing 
6B 
–0.573 0.075 
ARR3 Arrestin 3, retinal (X-arrestin) –0.497 0.076 
LMOD1 Leiomodin 1 (smooth muscle) –0.328 0.081 
LOC102546294 Uncharacterized LOC102546294 –0.427 0.085 
BAIAP2L1 BAI1-associated protein 2-like 1 –0.472 0.085 
SPINK2 Serine peptidase inhibitor, Kazal 
type 2 (acrosin-trypsin inhibitor) 
–0.545 0.090 
FGF14 Fibroblast growth factor 14 –0.509 0.092 
HMCN1 Hemicentin 1 –0.895 0.093 
ATG9B Autophagy related 9B –0.432 0.095 
ESRP2 Epithelial splicing regulatory 
protein 2 
–0.554 0.099 
CASC15 Cancer susceptibility candidate 
15 (non-protein coding) 
–0.472 0.103 
ZFHX3 Zinc finger homeobox 3 –0.340 0.103 
CLDN1 Claudin 1 –0.826 0.103 
SLC1A1 Solute carrier family 1 
(neuronal/epithelial high affinity 
glutamate transporter, system 
Xag), member 1 
–0.430 0.103 
LARGE-AS1 LARGE antisense RNA 1 –0.494 0.103 












i  inoma and melanoma linking higher mutational burden with greater
ffectiveness of immune checkpoint blockade therapy [ 52 , 53 ]. On the
ther hand, non–small-cell lung carcinoma and melanoma have a very
igh average mutational burden, unlike the relatively low average mu-
ational burden in DLBCL [54] , suggesting that factors other than TMB
ay be linked to the antitumoral immune response in DLBCL. ValidationDescargado para Anonymous User (n/a) en Vall d'Hebron Hospital de C
exclusivamente. No se permiten otros usos sin autorización. Copyf these results in larger patient samples is warranted to fully understand
heir clinical and biological significance. 
In FL, BCL2 mutations were more frequent in responders (75% vs.
8.6% in nonresponders). It has been proposed that BCL2 mutations in
L may be a surrogate for genomic instability triggered by activation-
nduced cytidine deaminase (AID) [55] . In FL, a significant associationlinicalKey.es por Elsevier en junio 14, 2021. Para uso personal 
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Table 5 
Most Enriched Pathways in Responders and Nonresponders to Ibrutinib plus Nivolumab among Patients with Non-Hodgkin’s Lymphoma a . 
Pathway Name NES FDR p Value FWER p Value 
Responders 
Translation b 2.98 0.000 0.000 
Metabolism of RNA b 2.93 0.000 0.000 
SRP-dependent co-translational protein targeting to membrane b 2.88 0.000 0.000 
IL12_2 pathway c 2.80 0.000 0.000 
HIV infection b 2.79 0.000 0.000 
Influenza life cycle b 2.79 0.000 0.000 
Metabolism of mRNA b 2.78 0.000 0.000 
Adaptive immune system b 2.73 0.000 0.000 
3UTR-mediated translational regulation b 2.71 0.000 0.000 
Host interactions of HIV factors b 2.71 0.000 0.000 
Processing of capped intron containing pre-mRNA b 2.68 0.000 0.000 
CD8 TCR pathway c 2.68 0.000 0.000 
TCR signaling b 2.67 0.000 0.000 
Interferon signaling b 2.66 0.000 0.000 
Respiratory electron transport ATP synthesis by chemiosmotic coupling and heat production by uncoupling proteins b 2.66 0.000 0.000 
TCA cycle and respiratory electron transport b 2.64 0.000 0.000 
Interferon gamma signaling b 2.63 0.000 0.000 
TCR pathway c 2.60 0.000 0.000 
Signaling by the BCR 2.59 0.000 0.000 
Antiviral mechanism by IFN-stimulated genes b 2.59 0.000 0.000 
Nonresponders 
Core matrisome d –2.92 0.000 0.000 
Integrin 1 pathway c –2.77 0.000 0.000 
ECM glycoproteins d –2.74 0.000 0.000 
Cytochrome P450 arranged by substrate type b –2.58 0.000 0.000 
ECM receptor interaction e –2.56 0.000 0.000 
ECM organization b –2.48 0.000 0.000 
Phase 1 functionalization of compounds b –2.48 0.000 0.000 
Regulation of IGF activity by IGF-binding proteins b –2.48 0.000 0.000 
Cell-cell junction organization b –2.41 0.000 0.000 
Collagen formation b –2.41 0.000 0.000 
A tetrasaccharide linker sequence is required for GAG synthesis b –2.38 0.000 0.000 
ECM regulators d –2.38 0.000 0.000 
Olfactory signaling pathway b –2.35 0.000 0.000 
Linoleic acid metabolism e –2.32 0.000 0.002 
Avb3 integrin pathway c –2.30 0.000 0.003 
Collagens d –2.29 0.000 0.003 
Tight junction interactions b –2.27 0.000 0.004 
Bile acid and bile salt metabolism b –2.25 0.000 0.009 
Cell junction organization b –2.24 0.000 0.009 
Integrin 3 pathway c –2.23 0.000 0.009 















































etween risk and TMB (also often used as a proxy for genomic instabil-
ty) has been previously demonstrated [56] . The lack of a distinct an-
icorrelation between TMB and response in the FL cohort of this study
compared with DLBCL) may indicate that there is some degree of bene-
t being derived from ibrutinib plus nivolumab therapy in genomically
nstable patients with high TMB FL. This is supported by the fact that
he patients with ≥ 30 mutated cancer-related genes in the set examined
n this work ( n = 1742) all had BCL2 mutations and a response rate of
5% (3/4; top two patients with the most mutations were responders),
hile the patients with response data who had < 10 mutated genes of
nterest had a 0% (0/2) response rate (neither had BCL2 mutations).
REBBP and KMT2D mutations were also frequent in FL, though not
ignificantly associated with response. Longitudinal analyses had previ-
usly identified CREBBP and KMT2D variants as early driver mutations
n chromatin regulator genes [29] . The mutational spectrum in RT in
his study was quite different than that observed in the other histolo-
ies. ROS1 was more frequent in RT nonresponders (2/4 vs. 0/13 in
esponders, p = 0.044); both ROS1 and BCL2 are involved in the NF- 𝜅B
athway. 
Gene expression analyses uncovered several genes and pathways dif-
erentially expressed in responders versus nonresponders to treatmentDescargado para Anonymous User (n/a) en Vall d'Hebron Hospital de C
exclusivamente. No se permiten otros usos sin autorización. Copyith ibrutinib plus nivolumab. The top genes upregulated in all patients
ho responded to ibrutinib plus nivolumab included LEF1 and BTLA.
EF1 is expressed at early stages of B-cell differentiation and is essen-
ial for cell survival and proliferation. Overexpression of LEF1 is asso-
iated with poor prognosis and disease progression in CLL [57] , and its
resence here may reflect the contribution of ibrutinib to the response.
TLA is a lymphocyte inhibitory receptor that is expressed on Th1 but
ot Th2 cells [58] . Increased BTLA expression in ibrutinib-responding
atients with NHL is consistent with the finding that ibrutinib can drive
h1- versus Th2 T-cell immunity [59] . Moreover, BTLA, TIGIT , and CCL4
re associated with T-cell exhaustion and tumor response to checkpoint
lockade [ 60 , 61 ]. Therefore, the fact that each of these genes is highly
pregulated in tumor tissue of responding patients suggests that the PD-
 blockade was also a significant part of the clinical efficacy in these
atients. 
In GCB DLBCL, CRTAM was the most upregulated gene in the respon-
ers. CRTAM is expressed on CD8 + T -cells, especially during late-stage
ctivation, and aids in maintaining activated T-cell populations within
ymph nodes [62] . A high level of CRTAM expression likely correlates
ith an immunologically active phenotype, potentially providing a ben-
fit for patients undergoing immune therapy for cancer. linicalKey.es por Elsevier en junio 14, 2021. Para uso personal 
right ©2021. Elsevier Inc. Todos los derechos reservados.



















































































































Overall, pathways upregulated in responders to ibrutinib plus
ivolumab were mostly related to RNA translation/metabolism, TCR,
L-12, IFN-gamma signaling, cytokine/chemokine activity, and general
mmune activation; similar trends are seen with DLBCL and RT alone.
hese results are consistent with studies reporting that PD-1 targets TCR
ignaling to inhibit functional T-cell activation [63] , and anti-PD-1 ther-
py reduces this inhibition. Moreover, successful activation of T cells
epends on a cross-talk between T cells and dendritic cells that involves
L-12 and IFN-gamma signaling [64] . IL-12 and IFN-gamma are also as-
ociated with Th1 differentiation [65] , and we have previously shown
ncreased secretion of these proteins in ibrutinib responders in FL [66] .
ased on two separate analyses in all patients and a subgroup of patients
ith DLBCL, our results suggest that patients showing high activity of
hese immune-related pathways may be more responsive to anti-PD-1
gents in combination with ibrutinib. Pathways related to BCR signal-
ng were also enriched in responders with FL, consistent with the mech-
nism of action of ibrutinib. 
Among all patients, nonresponders had enriched activity in pathways
elated to the ECM processing. A recently published study identified a
istinct set of ECM genes upregulated in cancer and correlated with poor
rognosis [67] . Transcriptional program dysregulation of these genes
as linked to the activation of TGF-beta signaling in cancer-associated
broblasts and subsequent immunosuppression [67] . The pathways ac-
ivated in the DLBCL nonresponders related mostly to cell cycle, DNA
eplication, and RNA splicing/processing/metabolism. These pathways
ay represent resistance mechanisms because they can drive cancer sur-
ival or progression using mechanisms that are not affected by ibrutinib
r nivolumab. Interestingly, some of the pathways enriched in respon-
ers with FL appeared to be implicated in RNA metabolism or trans-
ational regulation, possibly indicating high AID activity in responders.
s discussed previously, responder-associated BCL2 mutations in FL may
erve as a proxy for AID-mediated genomic instability. The DNA muta-
or activity of AID, which can ultimately serve to increase neoantigen
resentation and thereby response to checkpoint inhibition, is regulated
y the RNA exosome complex, meaning that RNA processing could be
elated to the mechanism behind many FL-associated BCL2 mutations
nd genomic instability [68] . 
In conclusion, there was a trend toward improved survival with ibru-
inib and nivolumab in patients with DLBCL with elevated PD-L1, al-
hough the differences did not reach statistical significance. We have
dentified several gene mutations, as well as differentially expressed
enes and enriched signaling pathways, in patients with DLBCL, FL, and
T who responded versus those who did not respond to treatment with
brutinib plus nivolumab. The preliminary analyses reported herein may
ighlight some of the mechanisms involved in the action of this thera-
eutic combination and help identify patients with B-cell malignancies
ho are most likely to benefit from treatment with ibrutinib combined
ith an anti-PD-1/PD-L1 agent, which may represent a salvage therapy
or patients with relapsed/refractory NHL. 
ole of the funding source 
Writing assistance was provided by Ewa Wandzioch and Liqing Xiao
f Parexel and funded by Janssen Global Services, LLC. 
ata-sharing statement 
The data in this publication will be available from the corresponding
uthor upon request. 
uthor contributions (per CRediT) 
Brendan P. Hodkinson: Conceptualization, Formal Analysis, Inves-
igation, Writing – Review & Editing; Michael Schaffer: Formal Analy-
is, Investigation, Writing – Review & Editing; Joshua D. Brody: Con-
eptualization, Formal Analysis, Investigation, Writing – Review & Edit-Descargado para Anonymous User (n/a) en Vall d'Hebron Hospital de C
exclusivamente. No se permiten otros usos sin autorización. Copyng; Wojciech Jurczak: Formal Analysis, Investigation, Writing – Re-
iew & Editing; Cecilia Carpio: Investigation, Writing – Review & Edit-
ng; Dina Ben-Yehuda: Investigation, Writing – Review & Editing; Irit
vivi: Investigation, Writing – Review & Editing; Ann Forslund : For-
al Analysis , Investigation, Writing – Review & Editing; Muhit Özcan:
nvestigation, Writing – Review & Editing; John Alvarez: Investigation,
riting – Review & Editing; Rob Ceulemans: Investigation, Writing –
eview & Editing; Nele Fourneau: Formal Analysis, Investigation, Writ-
ng – Review & Editing; Sriram Balasubramanian: Conceptualization,
nvestigation, Formal Analysis, Writing – Original Draft, Writing – Re-
iew & Editing; Anas Younes: Conceptualization, Investigation, Formal
nalysis, Writing – Original Draft, Writing – Review & Editing. 
eclaration of Competing Interest 
A. Younes received research funding from Novartis, Janssen, and
urtis and honoraria from Bayer, Merck, Bristol Myers Squibb, Celgene,
ncyte, Janssen, Sanofi, Seattle Genetics, and Takeda Millennium. W. Ju-
czak has served as a consultant or in an advisory role for Janssen-Cilag,
certa Pharma, Sandoz-Novartis, Celltrion, MEI Pharma, Roche, and
ilead Sciences and has received research funding from Janssen-Cilag,
certa Pharma, Merck, Gilead Sciences, TG Therapeutics, Pfizer, Incyte,
ayer HealthCare Pharmaceuticals, Sandoz-Novartis, Roche, Celltrion,
akeda Pharmaceuticals, Affimed Therapeutics, and Epizyme. M. Özcan
as received research funding from Archigen, AbbVie, Novartis, Bayer,
oche, MSD, Janssen, Celgene, and Takeda and honoraria and travel
unding from Takeda, Bristol Myers Squibb, JAZZ, Sanofi, Abdi İ brahim,
nd Roche. JD Brody received research funding from Janssen, Merck,
ristol Myers Squibb, Seattle Genetics, Takeda, Kite, Acerta, Celgene,
nd Morphosys. A. Forslund is an employee of Bristol Myers Squibb and
wns stock in the company. B. Hodkinson, M. Schaffer, N. Fourneau, J.
lvarez, R. Ceulemans, and S. Balasubramanian are employees of the
anssen Pharmaceutical Companies of Johnson & Johnson. S. Balasub-
amanian owns stock in Pharmacyclics/AbbVie. C. Carpio, I. Avivi, and
. Ben-Yehuda have nothing to disclose. 
cknowledgements 
The authors would like to thank all the patients who participated in
his study, as well as the study investigators. 
unding 
Sponsored by Janssen Research & Development, LLC. 
upplementary materials 
Supplementary material associated with this article can be found, in
he online version, at doi:10.1016/j.tranon.2020.100977 . 
eferences 
[1] J.C. Byrd , J.R. Brown , S. O’Brien , J.C. Barrientos , N.E. Kay , N.M. Reddy , et al. , Ibru-
tinib versus ofatumumab in previously treated chronic lymphoid leukemia, N. Engl.
J. Med. 371 (3) (2014) 213–223 . 
[2] S. O’Brien , R.R. Furman , S. Coutre , I.W. Flinn , J.A. Burger , K. Blum , et al. , Sin-
gle-agent ibrutinib in treatment-naive and relapsed/refractory chronic lymphocytic
leukemia: a 5-year experience, Blood 131 (17) (2018) 1910–1919 . 
[3] P.M. Barr , T. Robak , C. Owen , A. Tedeschi , O. Bairey , N.L. Bartlett , et al. , Sus-
tained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in
older patients with chronic lymphocytic leukemia: extended phase 3 results from
RESONATE-2, Haematologica 103 (9) (2018) 1502–1510 . 
[4] A. Chanan-Khan , P. Cramer , F. Demirkan , G. Fraser , R.S. Silva , S. Grosicki , et al. ,
Ibrutinib combined with bendamustine and rituximab compared with placebo, ben-
damustine, and rituximab for previously treated chronic lymphocytic leukaemia or
small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study,
Lancet Oncol. 17 (2) (2016) 200–211 . 
[5] A. Noy , V.S. de , C. Thieblemont , P. Martin , C.R. Flowers , F. Morschhauser , et al. ,
Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone
lymphoma, Blood 129 (16) (2017) 2224–2232 . linicalKey.es por Elsevier en junio 14, 2021. Para uso personal 
right ©2021. Elsevier Inc. Todos los derechos reservados.




















































































































[6] M.L. Wang , S. Rule , P. Martin , A. Goy , R. Auer , B.S. Kahl , et al. , Targeting BTK with
ibrutinib in relapsed or refractory mantle-cell lymphoma, N. Engl. J. Med. 369 (6)
(2013) 507–516 . 
[7] M.L. Wang , K.A. Blum , P. Martin , A. Goy , R. Auer , B.S. Kahl , et al. , Long-term fol-
low-up of MCL patients treated with single-agent ibrutinib: updated safety and effi-
cacy results, Blood 126 (6) (2015) 739–745 . 
[8] J.A. Burger , A. Tedeschi , P.M. Barr , T. Robak , C. Owen , P. Ghia , et al. , Ibrutinib as
initial therapy for patients with chronic lymphocytic leukemia, N. Engl. J. Med. 373
(25) (2015) 2425–2437 . 
[9] S.P. Treon , C.K. Tripsas , K. Meid , D. Warren , G. Varma , R. Green , et al. , Ibrutinib
in previously treated Waldenstrom’s macroglobulinemia, N. Engl. J. Med. 372 (15)
(2015) 1430–1440 . 
10] IMBRUVICA R ○ (ibrutinib) [prescribing information], Janssen Biotech, Inc., Horsham,
PA, USA, Pharmacyclics LLC, Sunnyvale, CA, USA, 2019 . 
11] IMBRUVICA (ibrutinib) [summary of Product Characteristics], Janssen-Cilag Inter-
national NV, Beerse, Belgium, 2019 [Internet]. [cited April 2, 2020]. Available from:
https://www.ema.europa.eu/en/documents/product-information/imbruvica-epar- 
product-information_en.pdf . 
12] N.H. Fowler , L. Nastoupil , S. De Vos , M. Knapp , I.W. Flinn , R. Chen , et al. , The
combination of ibrutinib and rituximab demonstrates activity in first-line follicular
lymphoma, Br. J. Haematol. 189 (4) (2020) 650–660 . 
13] W.H. Wilson , R.M. Young , R. Schmitz , Y. Yang , S. Pittaluga , G. Wright , et al. , Tar-
geting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma, Nat.
Med. 21 (8) (2015) 922–926 . 
14] N.L. Bartlett , B.A. Costello , B.R. LaPlant , S.M. Ansell , J.G. Kuruvilla , C.B. Reeder ,
et al. , Single-agent ibrutinib in relapsed or refractory follicular lymphoma: a phase
2 consortium trial, Blood 131 (2) (2018) 182–190 . 
15] S.M. Jaglowski , J.A. Jones , V. Nagar , J.M. Flynn , L.A. Andritsos , K.J. Maddocks ,
et al. , Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in
chronic lymphocytic leukemia: a phase 1b/2 study, Blood 126 (7) (2015) 842–850 .
16] A. Galaznik , R. Huelin , M. Stokes , Y. Guo , M. Hoog , T. Bhagnani , et al. , Systematic
review of therapy used in relapsed or refractory diffuse large B-cell lymphoma and
follicular lymphoma, Future Sci OA 4 (7) (2018) FSO322 . 
17] M. Yi , D. Jiao , H. Xu , Q. Liu , W. Zhao , X. Han , et al. , Biomarkers for predicting
efficacy of PD-1/PD-L1 inhibitors, Mol. Cancer 17 (1) (2018) 129 . 
18] Z.Y. Xu-Monette , J. Zhou , K.H Young , PD-1 expression and clinical PD-1 blockade
in B-cell lymphomas, Blood 131 (1) (2018) 68–83 . 
19] A. Younes , A. Santoro , M. Shipp , P.L. Zinzani , J.M. Timmerman , S. Ansell , et al. ,
Nivolumab for classical Hodgkin’s lymphoma after failure of both autologous stem–
cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm
phase 2 trial, Lancet Oncol. 17 (9) (2016) 1283–1294 . 
20] Y.L. Kasamon , R.A. de Claro , Y. Wang , Y.L. Shen , A.T. Farrell , R Pazdur , FDA ap-
proval summary: nivolumab for the treatment of relapsed or progressive classical
Hodgkin lymphoma, Oncologist 22 (5) (2017) 585–591 . 
21] A.M. Lesokhin , S.M. Ansell , P. Armand , E.C. Scott , A. Halwani , M. Gutierrez , et al. ,
Nivolumab in patients with relapsed or refractory hematologic malignancy: prelim-
inary results of a phase Ib study, J. Clin. Oncol. 34 (23) (2016) 2698–2704 . 
22] P. Armand, A.M. Janssens, G. Gritti, J. Radford, J.M. Timmerman, A. Pinto,
et al., Efficacy and safety results from CheckMate 140, a phase 2 study
of nivolumab for relapsed/refractory follicular lymphoma, Blood (2020),
doi: 10.1182/blood.2019004753 . 
23] N. Jain , A. Ferrajoli , U. Basu , T. P.A. , J.A Burger , A phase II trial of nivolumab com-
bined with ibrutinib for patients with Richter transformation, Blood 32 (Supplement
1) (2018) 296 . 
24] A. Younes , J. Brody , C. Carpio , A. Lopez-Guillermo , D. Ben-Yehuda , B. Ferhanoglu ,
et al. , Safety and activity of ibrutinib in combination with nivolumab in patients
with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase
1/2a study, Lancet Haematol. 6 (2) (2019) e67–e78 . 
25] P. Jain , S. O’Brien , Richter’s transformation in chronic lymphocytic leukemia, On-
cology 26 (12) (2012) 1146–1152 . 
26] M. Tsang , T.D. Shanafelt , T.G. Call , W. Ding , A. Chanan-Khan , J.F. Leis , et al. , The
efficacy of ibrutinib in the treatment of Richter syndrome, Blood 125 (10) (2015)
1676–1678 . 
27] J.G. Lohr , P. Stojanov , M.S. Lawrence , D. Auclair , B. Chapuy , C. Sougnez , et al. ,
Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma
(DLBCL) by whole-exome sequencing, Proc. Natl. Acad. Sci. U. S. A. 109 (10) (2012)
3879–3884 . 
28] H.Y. Park , S.B. Lee , H.Y. Yoo , S.J. Kim , W.S. Kim , J.I. Kim , et al. , Whole-exome and
transcriptome sequencing of refractory diffuse large B-cell lymphoma, Oncotarget 7
(52) (2016) 86433–86445 . 
29] J. Okosun , C. Bodor , J. Wang , S. Araf , C.Y. Yang , C. Pan , et al. , Integrated genomic
analysis identifies recurrent mutations and evolution patterns driving the initiation
and progression of follicular lymphoma, Nat. Genet. 46 (2) (2014) 176–181 . 
30] E. Chigrinova , A. Rinaldi , I. Kwee , D. Rossi , P.M. Rancoita , J.C. Strefford , et al. , Two
main genetic pathways lead to the transformation of chronic lymphocytic leukemia
to Richter syndrome, Blood 122 (15) (2013) 2673–2682 . 
31] G. Wright , B. Tan , A. Rosenwald , E.H. Hurt , A. Wiestner , L.M Staudt , A gene expres-
sion-based method to diagnose clinically distinct subgroups of diffuse large B cell
lymphoma, Proc. Natl. Acad. Sci. U. S. A. 100 (17) (2003) 9991–9996 . 
32] B.D. Cheson , R.I. Fisher , S.F. Barrington , F. Cavalli , L.H. Schwartz , E. Zucca ,
et al. , Recommendations for initial evaluation, staging, and response assessment of
Hodgkin and non-Hodgkin lymphoma: the Lugano classification, J. Clin. Oncol. 32
(27) (2014) 3059–3068 . 
33] R. Schmitz , G.W. Wright , D.W. Huang , C.A. Johnson , J.D. Phelan , J.Q. Wang , et al. ,
Genetics and pathogenesis of diffuse large B-cell lymphoma, N. Engl. J. Med. 378
(15) (2018) 1396–1407 . Descargado para Anonymous User (n/a) en Vall d'Hebron Hospital de C
exclusivamente. No se permiten otros usos sin autorización. Copy34] J.F. Novotny Jr. , J. Cogswell , H. Inzunza , C. Harbison , C. Horak , S Averbuch , Es-
tablishing a complementary diagnostic for anti-PD-1 immune checkpoint inhibitor
therapy, Ann. Oncol. 27 (10) (2016) 1966–1969 . 
35] L.Y. Hu , X.L. Xu , H.L. Rao , J. Chen , R.C. Lai , H.Q. Huang , et al. , Expression and
clinical value of programmed cell death-ligand 1 (PD-L1) in diffuse large B cell lym-
phoma: a retrospective study, Chin. J. Cancer 36 (1) (2017) 94 . 
36] J. Kiyasu , H. Miyoshi , A. Hirata , F. Arakawa , A. Ichikawa , D. Niino , et al. , Expression
of programmed cell death ligand 1 is associated with poor overall survival in patients
with diffuse large B-cell lymphoma, Blood 126 (19) (2015) 2193–2201 . 
37] D.J. Andorsky , R.E. Yamada , J. Said , G.S. Pinkus , D.J. Betting , J.M Timmerman ,
Programmed death ligand 1 is expressed by non-Hodgkin lymphomas and inhibits
the activity of tumor-associated T cells, Clin. Cancer Res. 17 (13) (2011) 4232–4244 .
38] B.J. Chen , B. Chapuy , J. Ouyang , H.H. Sun , M.G. Roemer , M.L. Xu , et al. , PD-L1
expression is characteristic of a subset of aggressive B-cell lymphomas and virus-as-
sociated malignancies, Clin. Cancer Res. 19 (13) (2013) 3462–3473 . 
39] S. Vranic , N. Ghosh , J. Kimbrough , N. Bilalovic , R. Bender , D. Arguello , et al. , PD-L1
status in refractory lymphomas, PLoS One 11 (11) (2016) e0166266 . 
40] P.K. Panjwani , V. Charu , M. DeLisser , H. Molina-Kirsch , Y. Natkunam , S Zhao , Pro-
grammed death-1 ligands PD-L1 and PD-L2 show distinctive and restricted patterns
of expression in lymphoma subtypes, Hum. Pathol. 71 (2018) 91–99 . 
41] X. Shi , S. Xiang , J. Cao , H. Zhu , B. Yang , Q. He , et al. , Kelch-like proteins: physiolog-
ical functions and relationships with diseases, Pharmacol. Res. 148 (2019) 104404 .
42] S. Li , J. Liu , Q. Min , T. Ikawa , S. Yasuda , Y. Yang , et al. , Kelch-like protein 14
promotes B-1a but suppresses B-1b cell development, Int. Immunol. 30 (7) (2018)
311–318 . 
43] J. Zhang , V. Grubor , C.L. Love , A. Banerjee , K.L. Richards , P.A. Mieczkowski , et al. ,
Genetic heterogeneity of diffuse large B-cell lymphoma, Proc. Natl. Acad. Sci. U. S.
A. 110 (4) (2013) 1398–1403 . 
44] J. Choi , J.D. Phelan , G.W. Wright , B. Haupl , D.W. Huang , A.L. Shaffer 3rd , et al. ,
Regulation of B cell receptor-dependent NF-kappaB signaling by the tumor suppres-
sor KLHL14, Proc. Natl. Acad. Sci. U. S. A. 117 (11) (2020) 6092–6102 . 
45] X. Li , W. Xu , W. Kang , S.H. Wong , M. Wang , Y. Zhou , et al. , Genomic analysis of
liver cancer unveils novel driver genes and distinct prognostic features, Theranostics
8 (6) (2018) 1740–1751 . 
46] J.A. van der Krogt , M.V. Bempt , J.F. Ferreiro , N. Mentens , K. Jacobs , U. Pluys , et al. ,
Anaplastic lymphoma kinase-positive anaplastic large cell lymphoma with the vari-
ant RNF213-, ATIC- and TPM3-ALK fusions is characterized by copy number gain of
the rearranged ALK gene, Haematologica 102 (9) (2017) 1605–1616 . 
47] R.S. Banh , C. Iorio , R. Marcotte , Y. Xu , D. Cojocari , A.A. Rahman , et al. , PTP1B
controls non-mitochondrial oxygen consumption by regulating RNF213 to promote
tumour survival during hypoxia, Nat. Cell Biol. 18 (7) (2016) 803–813 . 
48] D.B. Johnson , G.M. Frampton , M.J. Rioth , E. Yusko , Y. Xu , X. Guo , et al. , Targeted
next generation sequencing identifies markers of response to PD-1 blockade, Cancer
Immunol. Res. 4 (11) (2016) 959–967 . 
49] S. Kumar , N. Rao , R Ge , Emerging roles of ADAMTSs in angiogenesis and cancer,
Cancers 4 (4) (2012) 1252–1299 . 
50] D. Liao , Emerging roles of the EBF family of transcription factors in tumor suppres-
sion, Mol. Cancer Res. 7 (12) (2009) 1893–1901 . 
51] Y.S. Jo , M.S. Kim , N.J. Yoo , S.H Lee , Frameshift mutations of AKAP9 gene in gastric
and colorectal cancers with high microsatellite instability, Pathol. Oncol. Res. 22 (3)
(2016) 587–592 . 
52] N. Riaz , J.J. Havel , V. Makarov , A. Desrichard , W.J. Urba , J.S. Sims , et al. , Tumor
and microenvironment evolution during immunotherapy with nivolumab, Cell 171
(4) (2017) 934-49 e16 . 
53] P. Zarogoulidis , V. Papadopoulos , E. Maragouli , G. Papatsibas , C. Sardeli , Y.G. Man ,
et al. , Nivolumab as first-line treatment in non-small cell lung cancer patients-key
factors: tumor mutation burden and PD-L1 ≥ 50, Transl. Lung Cancer Res. 7 (Suppl
1) (2018) S28–S30 . 
54] M.S. Lawrence , P. Stojanov , P. Polak , G.V. Kryukov , K. Cibulskis , A. Sivachenko ,
et al. , Mutational heterogeneity in cancer and the search for new cancer-associated
genes, Nature 499 (7457) (2013) 214–218 . 
55] C. Correia , P.A. Schneider , H. Dai , A. Dogan , M.J. Maurer , A.K. Church , et al. , BCL2
mutations are associated with increased risk of transformation and shortened sur-
vival in follicular lymphoma, Blood 125 (4) (2015) 658–667 . 
56] T. Tsukamoto , M. Nakano , R. Sato , H. Adachi , M. Kiyota , E. Kawata , et al. , High-
-risk follicular lymphomas harbour more somatic mutations including those in the
AID-motif, Sci. Rep. 7 (1) (2017) 14039 . 
57] F. Erdfelder , M. Hertweck , A. Filipovich , S. Uhrmacher , K.A Kreuzer , High lymphoid
enhancer-binding factor-1 expression is associated with disease progression and poor
prognosis in chronic lymphocytic leukemia, Hematol Rep. 2 (1) (2010) e3 . 
58] N. Watanabe , M. Gavrieli , J.R. Sedy , J. Yang , F. Fallarino , S.K. Loftin , et al. , BTLA is a
lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1, Nat. Immunol.
4 (7) (2003) 670–679 . 
59] J.A. Dubovsky , K.A. Beckwith , G. Natarajan , J.A. Woyach , S. Jaglowski , Y. Zhong ,
et al. , Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective
pressure in T lymphocytes, Blood 122 (15) (2013) 2539–2549 . 
60] R.R. Ji , S.D. Chasalow , L. Wang , O. Hamid , H. Schmidt , J. Cogswell , et al. , An im-
mune-active tumor microenvironment favors clinical response to ipilimumab, Can-
cer Immunol. Immunother. 61 (7) (2012) 1019–1031 . 
61] X. Yu , K. Harden , L.C. Gonzalez , M. Francesco , E. Chiang , B. Irving , et al. , The surface
protein TIGIT suppresses T cell activation by promoting the generation of mature
immunoregulatory dendritic cells, Nat. Immunol. 10 (1) (2009) 48–57 . 
62] A. Takeuchi , Y. Itoh , A. Takumi , C. Ishihara , N. Arase , T. Yokosuka , et al. , CRTAM
confers late-stage activation of CD8 + T cells to regulate retention within lymph node,
J. Immunol. 183 (7) (2009) 4220–4228 . linicalKey.es por Elsevier en junio 14, 2021. Para uso personal 
right ©2021. Elsevier Inc. Todos los derechos reservados.












[  63] R. Mizuno , D. Sugiura , K. Shimizu , T. Maruhashi , M. Watada , I.M. Okazaki , et al. ,
PD-1 primarily targets TCR signal in the inhibition of functional T cell activation,
Front. Immunol. 10 (2019) 630 . 
64] C.S. Garris , S.P. Arlauckas , R.H. Kohler , M.P. Trefny , S. Garren , C. Piot ,
et al. , Successful anti-PD-1 Cancer immunotherapy requires T cell-dendritic cell
crosstalk involving the cytokines IFN-gamma and IL-12, Immunity 49 (6) (2018)
1148-61 e7 . 
65] V. Athie-Morales , H.H. Smits , D.A. Cantrell , C.M Hilkens , Sustained IL-12 signaling
is required for Th1 development, J. Immunol. 172 (1) (2004) 61–69 . Descargado para Anonymous User (n/a) en Vall d'Hebron Hospital de C
exclusivamente. No se permiten otros usos sin autorización. Copy66] A.K. Gopal , S.J. Schuster , N.H. Fowler , J. Trotman , G. Hess , J.Z. Hou , et al. , Ibrutinib
as treatment for patients with relapsed/refractory follicular lymphoma: results from
the open-label, multicenter, phase II DAWN study, J. Clin. Oncol. 36 (23) (2018)
2405–2412 . 
67] A. Chakravarthy , L. Khan , N.P. Bensler , P. Bose , D.D De Carvalho , TGF-beta-associ-
ated extracellular matrix genes link cancer-associated fibroblasts to immune evasion
and immunotherapy failure, Nat. Commun. 9 (1) (2018) 4692 . 
68] B. Laffleur , U. Basu , J Lim , RNA exosome and non-coding RNA-coupled mechanisms
in AID-mediated genomic alterations, J. Mol. Biol. 429 (21) (2017) 3230–3241 . linicalKey.es por Elsevier en junio 14, 2021. Para uso personal 
right ©2021. Elsevier Inc. Todos los derechos reservados.
